You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.
The society recommends routine use of multigene NGS for a handful of metastatic cancers, as well as in the context of clinical trials at academic centers.
Genetic testing results increasingly inform clinical decisions, though the inclusion of hereditary risk genes beyond BRCA1, BRCA2, and PALB2 sparked debate.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
By profiling hereditary risk variants in women with breast cancer, researchers hope to lay the foundation for future genetic testing programs in the Caribbean country.
The agency is excluding certain advanced diagnostic lab tests and molecular pathology tests from a billing regulation that created administrative headaches for many labs.